Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas on May 16, 2024.

Dr. Chunxia Lily Zhao, Director of Antibody Discovery at Astria Therapeutics, will present a poster titled, "Preclinical Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody" at Session One of the Pharmacology and Therapeutic Development Select E-Poster Discussions on May 16, 2024, at 5:00pm CDT.

About Astria Therapeutics :

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Falco Announces Resignation of Board Member

Falco Announces Resignation of Board Member

Falco Resources Ltd. (TSX-V: FPC) ( "Falco" or the " Corporation" ) announced today that Mr. Claude Dufresne has resigned as a member of the Board of Directors so that he may focus his efforts on other professional duties.

The Board of Directors would like to thank Mr. Dufresne for his contribution over the past few years and wish him well in his future endeavors.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Bold Options Claims in Ring of Fire Region

Bold Options Claims in Ring of Fire Region

Bold Ventures Inc. (TSXV:BOL) (the "Company" or "Bold") is pleased to announce that it has signed an option agreement (the "Agreement") to option a 100% interest in two claim groups (the "Optioned Claims") to an arms-length party (the "Optionee"). The claims are located in the Ring of Fire Region. The Optioned Claims were staked during a regional airborne Electromagnetic and Magnetic survey flown in 2013 for Bold Ventures and its co-Venturer, a subsidiary of Dundee Resources. The survey resulted in over 14 claim groups being staked at various times over two campaigns. The Optioned Claims have a combined area of approximately 2,595 acres (1,050 hectares) and comprise approximately 90 claim units. The Optioned Claims have seen very little exploration work in the past

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
WESTERN COPPER AND GOLD ANNOUNCES VOTING RESULTS FROM ANNUAL SHAREHOLDERS' MEETING

WESTERN COPPER AND GOLD ANNOUNCES VOTING RESULTS FROM ANNUAL SHAREHOLDERS' MEETING

western copper and gold corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) announces the voting results from the Company's Annual General and Special Meeting ("AGM") held on June 27, 2024.

Western Copper and Gold Corporation logo (CNW Group/Western Copper and Gold Corporation)

A total of 101,875,249 common shares were represented at the AGM, representing 51.92% of the votes attached to all outstanding common shares as at the record date.

Shareholders voted in favour of setting the number of directors at seven (7) and elected all directors, as follows:

Director

Votes For

% For

Votes Withheld

% Withheld

Robert Chausse

90,608,768

99.84 %

165,930

0.16 %

Tara Christie

82,647,749

90.20 %

8,979,661

9.80 %

Sandeep Singh

91,295,444

99.64 %

331,966

0.36 %

Raymond Threlkeld

90,876,101

98.85 %

1,018,642

1.11 %

Michael Vitton

87,843,574

95.87 %

3,783,836

4.13 %

Bill Williams

83,566,754

91.20 %

8,060,656

8.80 %

Klaus Zeitler

83,576,626

91.21 %

8,050,785

8.79 %

Shareholders also approved:  (i) the appointment of PricewaterhouseCoopers LLP as auditors of the Company and authorized the directors to set their remuneration, (ii) unallocated stock options under the Company's stock option plan, (iii) unallocated rights under the Company's deferred share unit plan, (iv) unallocated rights under the Company's restricted share unit plan.

The Company's report of voting results will be available on SEDAR ( www.sedar.com ), EDGAR ( www.sec.gov/edgar.shtml ), and on the Company's website.

ABOUT western copper and gold corporation

western copper and gold corporation is developing the Casino Project, Canada's premier copper-gold mine in the Yukon Territory and one of the most economic greenfield copper-gold mining projects in the world.

The Company is committed to working collaboratively with our First Nations and local communities to progress the Casino project, using internationally recognized responsible mining technologies and practices.  For more information, visit www.westerncopperandgold.com .

On behalf of the board,

"Sandeep Singh"

Sandeep Singh
Chief Executive Officer
western copper and gold corporation

SOURCE western copper and gold corporation

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2024/27/c2084.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
FALCO ANNOUNCES CLOSING OF FIRST TRANCHE OF BROKERED PRIVATE PLACEMENT

FALCO ANNOUNCES CLOSING OF FIRST TRANCHE OF BROKERED PRIVATE PLACEMENT

TSX.V - FPC

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Forte Minerals Corp. Closes Oversubscribed Private Placement Offering

Forte Minerals Corp. Closes Oversubscribed Private Placement Offering

(Not for distribution to United States newswire services or for dissemination in the United States of America)

Forte Minerals Corp. ("Forte" or the "Company") (CSE:CUAU)(OTCQB:FOMNF)(Frankfurt:2OA), is pleased to announce the closing of its previously announced non-brokered private placement (the "Offering") (see press release dated June 5, 2024). The Offering was initially set for 7,500,000 units but, due to high demand, was oversubscribed, resulting in the issuance of 8,953,000 units at a price of CAD $0.20 per unit for aggregate gross proceeds of CAD $1,790,600

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Aston Bay Announces Planned Exploration Program at its Epworth Sediment Hosted Copper-Silver-Zinc-Cobalt Project, Nunavut, Canada

Aston Bay Announces Planned Exploration Program at its Epworth Sediment Hosted Copper-Silver-Zinc-Cobalt Project, Nunavut, Canada

Airborne geophysics, structural mapping, and sampling to define drill targets

Aston Bay Holdings Ltd. (TSX-V:BAY)(OTCQB:ATBHF) (the "Company" or "Aston Bay") is pleased to announce the proposed summer 2024 exploration program at its Epworth sediment hosted copper-silver-zinc-cobalt project located 80 kilometres ("km") southeast of Kugluktuk in Nunavut, Canada

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×